Daiichi Sankyo Co. Ltd.
Company Snapshot
Founded: 2005
Entity Type: Public
Employees: 19,765
Region: Japan
Revenue: $12,392.7 Millions
Revenue Year: 2024
Headquarter: Japan
Key Geographics: North America, Europe, Japan, Other Regions
Corporate Address: 3-5-1, Nihonbashi-honcho Chuo-ku, Tokyo 103-8426 Japan 81-3-6225-1111 www.daiichisankyo.com
Company Overview
Daiichi Sankyo, formed through the merger of Daiichi Pharmaceutical and Sankyo, is a biopharmaceutical company. It offers branded and generic medicines and new drug discovery and delivery methods. The company manages business in two segments: Prescription drugs and healthcare (OTC) products. The company’s prescription division focuses on oncology, central nervous system, cardiovascular, and ophthalmic disease. Gene therapy is a significant area of interest for the company. Daiichi Sankyo sells its products in 29 countries/regions around the world.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Daiichi Sankyo Co. Ltd. In Reports
Daiichi Sankyo Co. Ltd. In News
Company's Business Segments
- Pharmaceutical Operation : Under this segment, the company provides Oncology, Cardiovascular, Other Pharmaceuticals, and Vaccines.
Applications/End User Industries
- Healthcare
- Pharmaceuticals
BCC Research Beacon 